176 related articles for article (PubMed ID: 22092298)
1. Methadone inhibits CYP2D6 and UGT2B7/2B4 in vivo: a study using codeine in methadone- and buprenorphine-maintained subjects.
Gelston EA; Coller JK; Lopatko OV; James HM; Schmidt H; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 May; 73(5):786-94. PubMed ID: 22092298
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of CYP2D6-mediated tramadol O-demethylation in methadone but not buprenorphine maintenance patients.
Coller JK; Michalakas JR; James HM; Farquharson AL; Colvill J; White JM; Somogyi AA
Br J Clin Pharmacol; 2012 Nov; 74(5):835-41. PubMed ID: 22369095
[TBL] [Abstract][Full Text] [Related]
3. In vitro-in vivo extrapolation predicts drug-drug interactions arising from inhibition of codeine glucuronidation by dextropropoxyphene, fluconazole, ketoconazole, and methadone in humans.
Raungrut P; Uchaipichat V; Elliot DJ; Janchawee B; Somogyi AA; Miners JO
J Pharmacol Exp Ther; 2010 Aug; 334(2):609-18. PubMed ID: 20484152
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the antinociceptive effect of morphine, methadone, buprenorphine and codeine in two substrains of Sprague-Dawley rats.
Bulka A; Kouya PF; Böttiger Y; Svensson JO; Xu XJ; Wiesenfeld-Hallin Z
Eur J Pharmacol; 2004 May; 492(1):27-34. PubMed ID: 15145702
[TBL] [Abstract][Full Text] [Related]
5. O-demethylation of codeine to morphine inhibited by low-dose levomepromazine.
Vevelstad M; Pettersen S; Tallaksen C; Brørs O
Eur J Clin Pharmacol; 2009 Aug; 65(8):795-801. PubMed ID: 19308365
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication.
Kirchheiner J; Schmidt H; Tzvetkov M; Keulen JT; Lötsch J; Roots I; Brockmöller J
Pharmacogenomics J; 2007 Aug; 7(4):257-65. PubMed ID: 16819548
[TBL] [Abstract][Full Text] [Related]
7. The pharmacogenetics of codeine hypoalgesia.
Sindrup SH; Brøsen K
Pharmacogenetics; 1995 Dec; 5(6):335-46. PubMed ID: 8845855
[TBL] [Abstract][Full Text] [Related]
8. Evidence for morphine-independent central nervous opioid effects after administration of codeine: contribution of other codeine metabolites.
Lötsch J; Skarke C; Schmidt H; Rohrbacher M; Hofmann U; Schwab M; Geisslinger G
Clin Pharmacol Ther; 2006 Jan; 79(1):35-48. PubMed ID: 16413240
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomics of codeine, morphine, and morphine-6-glucuronide: model-based analysis of the influence of CYP2D6 activity, UGT2B7 activity, renal impairment, and CYP3A4 inhibition.
Eissing T; Lippert J; Willmann S
Mol Diagn Ther; 2012 Feb; 16(1):43-53. PubMed ID: 22352453
[TBL] [Abstract][Full Text] [Related]
10. Post-mortem levels and tissue distribution of codeine, codeine-6-glucuronide, norcodeine, morphine and morphine glucuronides in a series of codeine-related deaths.
Frost J; Løkken TN; Helland A; Nordrum IS; Slørdal L
Forensic Sci Int; 2016 May; 262():128-37. PubMed ID: 26986973
[TBL] [Abstract][Full Text] [Related]
11. The impact of CYP2D6 polymorphisms on the pharmacokinetics of codeine and its metabolites in Mongolian Chinese subjects.
Wu X; Yuan L; Zuo J; Lv J; Guo T
Eur J Clin Pharmacol; 2014 Jan; 70(1):57-63. PubMed ID: 24077935
[TBL] [Abstract][Full Text] [Related]
12. Different effects of inhibitors on the O- and N-demethylation of codeine in human liver microsomes.
Yue QY; Säwe J
Eur J Clin Pharmacol; 1997; 52(1):41-7. PubMed ID: 9143866
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of 3'-azido-3'-deoxythymidine, morphine, and codeine as probe substrates for UDP-glucuronosyltransferase 2B7 (UGT2B7) in human liver microsomes: specificity and influence of the UGT2B7*2 polymorphism.
Court MH; Krishnaswamy S; Hao Q; Duan SX; Patten CJ; Von Moltke LL; Greenblatt DJ
Drug Metab Dispos; 2003 Sep; 31(9):1125-33. PubMed ID: 12920168
[TBL] [Abstract][Full Text] [Related]
14. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic determination of the effects of codeine and prediction of drug interactions.
Caraco Y; Sheller J; Wood AJ
J Pharmacol Exp Ther; 1996 Sep; 278(3):1165-74. PubMed ID: 8819499
[TBL] [Abstract][Full Text] [Related]
16. Impact of quinidine on plasma and cerebrospinal fluid concentrations of codeine and morphine after codeine intake.
Sindrup SH; Hofmann U; Asmussen J; Mikus G; Brøsen K; Nielsen F; Ingwersen SH; Broen Christensen C
Eur J Clin Pharmacol; 1996; 49(6):503-9. PubMed ID: 8706777
[TBL] [Abstract][Full Text] [Related]
17. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.
Caraco Y; Tateishi T; Guengerich FP; Wood AJ
Drug Metab Dispos; 1996 Jul; 24(7):761-4. PubMed ID: 8818573
[TBL] [Abstract][Full Text] [Related]
18. Functional phenotyping of the CYP2D6 probe drug codeine in the horse.
Gretler SR; Finno CJ; Kass PH; Knych HK
BMC Vet Res; 2021 Feb; 17(1):77. PubMed ID: 33581736
[TBL] [Abstract][Full Text] [Related]
19. On the assessment of drug metabolism by assays of codeine and its main metabolites.
Haffen E; Paintaud G; Berard M; Masuyer C; Bechtel Y; Bechtel PR
Ther Drug Monit; 2000 Jun; 22(3):258-65. PubMed ID: 10850391
[TBL] [Abstract][Full Text] [Related]
20. Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes.
Tseng CY; Wang SL; Lai MD; Lai ML; Huang JD
Clin Pharmacol Ther; 1996 Aug; 60(2):177-82. PubMed ID: 8823235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
